Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233558 · ClinicalTrials.gov registry record · Phase 4
Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis
A Phase 4 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT00233558: Clinical Trial Phase 4 study, sponsored by Abbott.
NCT00233558 is a Phase 4 study that was terminated before completion, run by Abbott. The registered enrollment target is 160 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00233558, a Phase 4 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active RA treated with adalimumab + MTX
Interventions
- DRUG methotrexate
- DRUG adalimumab (up to 9 months exposure)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2005-06 |
| Phase | Phase 4 |
Why NCT00233558 stopped before completion
NCT00233558 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which methotrexate is the first listed.
NCT00233558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00233558 about?
NCT00233558 is a clinical study titled "Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis". The purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active RA treated with adalimumab + MTX
What is the current status of trial NCT00233558?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2005-06.
What interventions are being tested in trial NCT00233558?
The interventions under investigation include: methotrexate (DRUG), adalimumab (up to 9 months exposure) (DRUG).
Who is sponsoring clinical trial NCT00233558?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00233558's enrollment target sits among peer trials
160 507th of 2000 higher than 1,485 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia